Key result
All 500 mg aspirin formulations provided comparable overall plasma exposure, while effervescent tablets, fast-release tablets, and granules in suspension achieved higher Cmax and shorter Tmax.
Why the study?
How do different formulations of 500 mg aspirin affect the pharmacokinetic parameters of acetylsalicylic acid and salicylic acid?
Population
Data from 22 pharmacokinetic studies from Bayer's clinical trial database evaluating 500 mg aspirin…
Comparison
Various 500 mg aspirin formulations vs Plain tablets and dry granules (500 mg aspirin)
Design
Meta-analysis
Authors
Loading...
Formulation differences may affect aspirin absorption speed in acute use; leaves open whether PK variations alter clinical efficacy or safety.
How do different formulations of 500 mg aspirin affect the pharmacokinetic parameters of acetylsalicylic acid and salicylic acid?
Different formulations of 500 mg aspirin provide comparable overall exposure but differ significantly in absorption rate, with effervescent and fast-release formulations achieving faster and higher peak concentrations.
Kanani et al. (2015) conducted a review in Healthy volunteers. Aspirin formulations (effervescent, granules, chewable, fast-release) vs. Aspirin plain tablets was evaluated on Pharmacokinetic parameters including AUC, Cmax, and Tmax for acetylsalicylic acid and salicylic acid. All 500 mg aspirin formulations provided comparable overall plasma exposure, while effervescent tablets, fast-release tablets, and granules in suspension achieved higher Cmax and shorter Tmax.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: